Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Tressa Hood"'
Autor:
Maj-Britt Jensen, Anne-Vibeke Lænkholm, Torsten O. Nielsen, Jens Ole Eriksen, Pernille Wehn, Tressa Hood, Namratha Ram, Wesley Buckingham, Sean Ferree, Bent Ejlertsen
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)
Abstract Background The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for women with high-risk breast cancer. We investigate the predictive ability of Prosigna regarding the effectiveness of cyclophospham
Externí odkaz:
https://doaj.org/article/4673ff5f6aca4466993ba61ac60353e3
Publikováno v:
OncoImmunology, Vol 8, Iss 9 (2019)
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients yet little is known about the microenvironment that supports this aggressive disease. We have used targeted gene expression profiling and immunohistochem
Externí odkaz:
https://doaj.org/article/f7ede3e5c62d4f9f94dba887ac06b337
Autor:
Douglas C. Saffran, Melinda A.L. Day, Nathalie Rioux, Tom Chen, Christina Lee, Suha Naffar-Abu Amara, David B. Freeman, Tressa Hood, Charles Y. Lin, Pavan Kumar, Jorge DiMartino
Publikováno v:
Cancer Research. 82:P5-08
KB-0742 is an orally available, potent, and selective inhibitor of cyclin-dependent kinase 9 (CDK9). Sensitivity profiling across a panel of 800 adherent and suspension immortalized pan-cancer cell lines using the Broad Institute PRISM platform had p
Autor:
Luis A. Carvajal, Michael McKeown, Tressa Hood, Pavan Kumar, Douglas C. Saffran, Jorge DiMartino
Publikováno v:
Blood. 140:5932-5933
Autor:
Luis A. Carvajal, Tressa Hood, Yana Bevan, Richard Dillon, Nicola Potter, Ian Thomas, Sean Johnson, Jad Othman, Amanda Gilkes, Nigel H. Russell, Adam Sikorski, Pete Ellis, Giovanni Marsico, Greg Jones, Crystal MacKenzie, Zung To, Jorge DiMartino, Pavan Kumar
Publikováno v:
Blood. 140:3377-3378
Autor:
Ibrahim Aldoss, Ivana Gojo, Tung On Yau, Anbarasu Lourdusamy, Anjali S. Advani, Catherine Lai, Martin Bornhäuser, John F. DiPersio, Heidi Altmann, Martha Arellano, Michael P. Rettig, Bob Löwenberg, Stephen Reeder, Peter J. M. Valk, Jan K Davidson-Moncada, John E. Godwin, Sarah E. Church, Kendra Sweet, Jan Moritz Middeke, Tressa Hood, Friedrich Stölzel, John Muth, Gemma A. Foulds, Sergio Rutella, Farhad Ravandi, Jayakumar Vadakekolathu, Matthew J. Wieduwilt, Antonio Curti, Marilena Ciciarello
Publikováno v:
Blood Adv
Blood advances, 4(20), 5011-5024. American Society of Hematology
Blood advances, 4(20), 5011-5024. American Society of Hematology
Somatic TP53 mutations and 17p deletions with genomic loss of TP53 occur in 37% to 46% of acute myeloid leukemia (AML) with adverse-risk cytogenetics and correlate with primary induction failure, high risk of relapse, and dismal prognosis. Herein, we
Autor:
Suha Naffar-Abu Amara, Christina Noe, Tressa Hood, Sara Paganini, Crystal MacKenzie, Melinda A. Day, Pavan Kumar
Publikováno v:
Cancer Research. 82:535-535
Liquid biopsies analyzing cell-free DNA (cfDNA) released by tumors are emerging as a powerful noninvasive sampling approach. As opposed to single-site solid tumor biopsy, liquid biopsies allow for better representation of the tumor mutational landsca
Autor:
Melinda A. Day, Douglas C. Saffran, Tressa Hood, Nikolaus Obholzer, Akanksha Pandey, Charles Y. Lin, Pavan Kumar, Jorge DiMartino
Publikováno v:
Cancer Research. 82:2639-2639
MYC is an early-response gene downstream of many receptor complexes, and a component that promotes several pro-growth signal transduction pathways. As a result, MYC expression is highly regulated, but once dysregulated in cancer, MYC promotes tumorig
Autor:
Melinda A. Day, Douglas C. Saffran, Tressa Hood, Nikolaus Obholzer, Akanksha Pandey, Charles Y. Lin, Pavan Kumar, Daniel M. Freed, Jorge DiMartino
Publikováno v:
Cancer Research. 82:2564-2564
Lineage-specific transcriptional networks drive cellular differentiation and development. Disruption of these specific cell programs can result in cancer and create a subset of tumors that are “transcriptionally addicted.” Sarcomas, for example,
Autor:
Melinda A. Day, Douglas C. Saffran, Tressa Hood, Nikolaus Obholzer, Akanksha Pandey, Charles Y. Lin, Pavan Kumar, Jorge DiMartino
Publikováno v:
Cancer Research. 82:2565-2565
Small-cell lung cancer (SCLC) is a highly aggressive malignancy, with a 5-year survival rate below 5%. In contrast to non-small cell lung cancer, in which treatment advancements have shown much success, there has not been significant progress in the